TY  - JOUR
T1  - The Effects of Levetiracetam as an Antiepileptic on Vitamin D3 Levels in Iraqi Patients with a History of Epilepsy
AU - Al‐Balkhi, Ali M.
        AU - Khadir, Faris
        AU - Al-Sammak, Wameedh Q.
        AU - Al-Alwany, Ameen
        
JO  - ACE Journal of Urology
VL  - 1
IS  - 1
SP  - 1
EP  - 5
PY  - 2024
DA  - 2001/08/19
SN  - 2520-5684
DO  - 10.36478/aceju.2024.1.7
UR  - https://theacepublications.com/article-detail.php?art=258-ACE-JU
KW  - Levetiracetam
KW  - epilepsy
KW  - vitamin D3
KW  - calcium
KW  - ALP
AB  - Levetiracetam, a newer antiepileptic drug (AED), is commonly prescribed
due to its efficacy and safety profile. However, its effects on Vitamin D3
levels and bone health remain uncertain, particularly in long‐term
monotherapy. This study aimed to evaluate the effects of Levetiracetam
monotherapy on Vitamin D3 levels, serum calcium and alkaline
phosphatase (ALP) among Iraqi patients with epilepsy. This
cross‐sectional prospective study included 32 patients diagnosed with
generalized or focal epilepsy. All patients received Levetiracetam
monotherapy (1000‐3000) mg/day for at least 6 months. Vitamin D3
levels, calcium levels and ALP values were analyzed. Results were
presented in tables, percentages and correlations with dose and
duration. The results showed that(35.3%) of patients had severe Vitamin
D3 deficiency (<20) ng/ml, while (41.2%) had moderate Vitamin D3
deficiency (20‐30) ng/ml. Normal Vitamin D3 levels (>30) ng/ml were
observed in only (23.5%). A strong negative correlation (R=‐0.54) was
found between Vitamin D3 levels and Levetiracetam dose. Calcium
deficiency was noted in (17.6%) of patients and (11.8%) had abnormal
ALP levels. Levetiracetam monotherapy, particularly at higher doses, is
associated with reduced Vitamin D3 levels and potential risks to bone
health. Regular monitoring and supplementation are recommended to
mitigate these effects.
ER  -